MDP.TO WACC - Weighted Average Cost of Capital

The WACC of Medexus Pharmaceuticals Inc (MDP.TO) is 9.4%.

The Cost of Equity of Medexus Pharmaceuticals Inc (MDP.TO) is 10.45%.

The Cost of Debt of Medexus Pharmaceuticals Inc (MDP.TO) is 7.85%.

	Range	Selected
Cost of equity	8.60% - 12.30%	10.45%
Tax rate	25.90% - 26.50%	26.20%
Cost of debt	7.30% - 8.40%	7.85%
WACC	7.9% - 11.0%	9.4%

WACC

MDP.TO WACC calculation

Category	Low	High

Long-term bond rate	3.2%	3.7%
Equity market risk premium	5.1%	6.1%
Adjusted beta	1.06	1.34

Additional risk adjustments	0.0%	0.5%
Cost of equity	8.60%	12.30%

Tax rate	25.90%	26.50%
Debt/Equity ratio	0.29	0.29
Cost of debt	7.30%	8.40%

After-tax WACC	7.9%	11.0%


Selected WACC	9.4%

MDP.TO's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for MDP.TO:

cost_of_equity (10.45%) = risk_free_rate (3.45%) + equity_risk_premium (5.60%) * adjusted_beta (1.06) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.